Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brett Stevens

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Leukemia & Lymphoma|September 22, 2015
Clonality of neutrophilia associated with plasma cell neoplasms: report of a SETBP1 mutation and analysis of a single institution seriesBrett Stevens, Julia Maxson, Jeffrey Tyner, et al.
Cell Stem Cell|July 5, 2016
Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to an Adipose Tissue NicheHaobin Ye, Biniam Adane, Nabilah Khan, et al.
The Journal of Clinical Investigation|March 2, 2016
MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemiaSimone S Riedel, Jessica N Haladyna, Matthew Bezzant, et al.
JCI Insight|August 26, 2020
ETV6 germline mutations cause HDAC3/NCOR2 mislocalization and upregulation of interferon response genesMarlie H Fisher, Gregory D Kirkpatrick, Brett Stevens, et al.
Blood Advances|October 5, 2021
Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemiaEvan M Cherry, Diana Abbott, Maria Amaya, et al.
Leukemia Research|April 23, 2019
Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysisBrett Stevens, Amanda Winters, Jonathan A Gutman, et al.
JCO Clinical Cancer Informatics|October 4, 2022
Machine Learning-Based Exploratory Clinical Decision Support for Newly Diagnosed Patients With Acute Myeloid Leukemia Treated With 7 + 3 Type Chemotherapy or Venetoclax/AzacitidineNazmul Islam, Jamie S Reuben, Justin Dale, et al.
Haematologica|April 13, 2023
Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemiaJonathan A Gutman, Amanda Winters, Andrew Kent, et al.
Haematologica|June 27, 2024
Lysosomal acid lipase A modulates leukemia stem cell response to venetoclax/tyrosine kinase inhibitor combination therapy in blast phase chronic myeloid leukemiaMohd Minhajuddin, Amanda Winters, Haobin Ye, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Leukemia & Lymphoma|September 22, 2015
Clonality of neutrophilia associated with plasma cell neoplasms: report of a SETBP1 mutation and analysis of a single institution seriesBrett Stevens, Julia Maxson, Jeffrey Tyner, et al.
Cell Stem Cell|July 5, 2016
Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to an Adipose Tissue NicheHaobin Ye, Biniam Adane, Nabilah Khan, et al.
The Journal of Clinical Investigation|March 2, 2016
MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemiaSimone S Riedel, Jessica N Haladyna, Matthew Bezzant, et al.
JCI Insight|August 26, 2020
ETV6 germline mutations cause HDAC3/NCOR2 mislocalization and upregulation of interferon response genesMarlie H Fisher, Gregory D Kirkpatrick, Brett Stevens, et al.
Blood Advances|October 5, 2021
Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemiaEvan M Cherry, Diana Abbott, Maria Amaya, et al.
Leukemia Research|April 23, 2019
Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysisBrett Stevens, Amanda Winters, Jonathan A Gutman, et al.
JCO Clinical Cancer Informatics|October 4, 2022
Machine Learning-Based Exploratory Clinical Decision Support for Newly Diagnosed Patients With Acute Myeloid Leukemia Treated With 7 + 3 Type Chemotherapy or Venetoclax/AzacitidineNazmul Islam, Jamie S Reuben, Justin Dale, et al.
Haematologica|April 13, 2023
Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemiaJonathan A Gutman, Amanda Winters, Andrew Kent, et al.
Haematologica|June 27, 2024
Lysosomal acid lipase A modulates leukemia stem cell response to venetoclax/tyrosine kinase inhibitor combination therapy in blast phase chronic myeloid leukemiaMohd Minhajuddin, Amanda Winters, Haobin Ye, et al.
Pageof 2